International Association for the Study of Lung Cancer (IASLC) shared on LinkedIn:
“WCLC26 recap
Dr. Pedro Rocha said data from the DeLLphi-308 study indicate that subcutaneous tarlatamab can achieve serum exposures comparable to intravenous administration in a heavily pretreated population.
Read the presentation highlights in ILCN.”
You can also read:
DeLLphi-305: Durvalumab + Tarlatamab Improves Survival in First-Line ES-SCLC
